

Tricia Kennerley

VP, Director of International Public Affairs Walgreens Boots Alliance

European Industrial Pharmacists Group Symposium 2017



19 May, 2017

Three Success Stories Coming Together

The first global pharmacy-led, health and wellbeing enterprise















Two iconic retail pharmacy brands and a leading international pharmaceutical wholesaler



Our Growing Global Presence





^{*}Countries where the Company's products are available for purchase or there are Company franchises (other than those countries where there are owned businesses, equity method investments or joint ventures)

About Us

Presence in more than 25* countries

Over 400,000* people employed

One of the world's largest purchasers of prescription drugs and many other health and wellbeing products

The largest retail pharmacy,
health and daily living
destination in the
USA and Europe


A global leader in pharmacy-led, health and wellbeing retail with over **13,200*** stores in **11*** countries

One of the largest global pharmaceutical wholesale and distribution networks with over **390*** distribution centers in **20*** countries



^{*} Figures as of 31st August 2016, including equity method investments, using publicly available information for AmerisourceBergen.

We've always been at the forefront of new distribution models




Precision medicines are expensive compared to conventional medicines

- Increased working-capital needed?
- Stock holding ability
- New equipment/facilities to be funded
- Loss/damage of product



European Distribution Centre

High cost medicine orders from the local market are distributed from the Alloga European Distribution Centre directly to hospitals or specialist clinics in 24 hours (hub and spoke model)



The genome specific treating
Hep C drug Sovaldi costs
c€14k per pack



Sovaldi[™] fosbuvir) Tablet

Glybera – a gene therapy – costs \$1m per treatment




Medicines innovation is driving non-traditional models

- Patient Access Schemes
- Unlicensed drugs
- Unforeseen future requirements
 - Clinical
 - Regulatory

Companies that source and supply unlicensed medicines







Handling requirements differ

- Specific temperatures
- Packaging
- Fragile products
- Outer packaging/dose-relationship
- Handling, e.g. sterile environments
- New facilities, equipment, training, SOPs

Alcura cold chain validation

- Medicines packed in insulated boxes with cold/frozen packs
- Packed in validated way controlled by SOPs to maintain cold chain conditions for at least 48 hours (summer and winter)
- Medicines can be removed from vehicle, kept at place of work and stored without using 'staff fridge', or be returned
 all within controlled supply chain so can be reused











Increasing number and type of manufacturing facilities

- Efficient and responsive distribution of biomarker and their drug treatments
- Shelf-life of medicines
- Specialist manufacturing, e.g. lab vs hospital





3D printing could allow for nearpatient printing of a 'personalized pill'



Need for patient support increases

- Pharmacy vs homecare delivery
- Patient support programmes
- Adverse events profiles
- New training
- Funding
- Batch recall
- Testing prior to treatment



Pharmacist-led vaccination piloted (not yet nationwide)



More outcome measurement and feedback loops to clinicians

- Pharmacist education changing
- Reimbursement reliant on outcomes
- Monitoring / testing
 - Use of technology
 - HCP (e.g. homecare) collect data, or bypass HCP?
 - Patient / automatic
 - Adverse event reporting
- Labelling / tagging and tracking





Creating an entirely new big data set



Consumers

- Convenience
- Fast, efficient prescription fulfilment
- Speed of collection
- Stock availability
- 'Online banking



Pharmacies

- Control over workload
- Workflow management



Manufacturers

- Improved Adherence
- Access to consumer
- Information and insight

Data / CRM / Service Orientated (API)
Extending the supply chain – true pallet to patient



Working together for the benefit of the patient



Trust

Care

Partnership

Dedication

Innovation



Thank You

Tricia Kennerley

Email: tricia.kennerley@wba.com

Telephone: +44 7768 902679

